- Home
- AWP vs RIGL Comparison
AWP vs RIGL Comparison
Compare AWP & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AWP
- RIGL
- Stock Information
- Founded
- AWP 2007
- RIGL 1996
- Country
- AWP United States
- RIGL United States
- Employees
- AWP N/A
- RIGL N/A
- Industry
- AWP Trusts Except Educational Religious and Charitable
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- AWP Finance
- RIGL Health Care
- Exchange
- AWP Nasdaq
- RIGL Nasdaq
- Market Cap
- AWP 346.7M
- RIGL 335.5M
- IPO Year
- AWP N/A
- RIGL 2000
- Fundamental
- Price
- AWP $3.99
- RIGL $38.85
- Analyst Decision
- AWP
- RIGL Buy
- Analyst Count
- AWP 0
- RIGL 5
- Target Price
- AWP N/A
- RIGL $38.20
- AVG Volume (30 Days)
- AWP 331.5K
- RIGL 995.6K
- Earning Date
- AWP 01-01-0001
- RIGL 08-05-2025
- Dividend Yield
- AWP 12.48%
- RIGL N/A
- EPS Growth
- AWP N/A
- RIGL N/A
- EPS
- AWP N/A
- RIGL 5.43
- Revenue
- AWP N/A
- RIGL $267,921,000.00
- Revenue This Year
- AWP N/A
- RIGL $59.93
- Revenue Next Year
- AWP N/A
- RIGL N/A
- P/E Ratio
- AWP N/A
- RIGL $7.15
- Revenue Growth
- AWP N/A
- RIGL 105.62
- 52 Week Low
- AWP $3.06
- RIGL $12.66
- 52 Week High
- AWP $4.20
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- AWP 63.22
- RIGL 68.57
- Support Level
- AWP $3.95
- RIGL $39.00
- Resistance Level
- AWP $4.01
- RIGL $42.08
- Average True Range (ATR)
- AWP 0.04
- RIGL 2.32
- MACD
- AWP 0.01
- RIGL -0.37
- Stochastic Oscillator
- AWP 85.71
- RIGL 53.26
About AWP abrdn Global Premier Properties Fund of Beneficial Interest
Aberdeen Global Premier Properties Fund is a diversified, closed-end management investment company. Its objective is to seek high current income and capital appreciation. It predominantly invests in equity and debt securities of domestic and foreign issuers which are principally engaged in the real estate industry, real estate financing or control real estate assets. Its portfolio of investments consists securities of Industrial REITs, Retail REITs, Data Center REITs, Health Care REITs and others.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.